Humacyte

It was great to hear from Dr. Ernest Moore, Dr. Joe Dubose, and Dr. Laura Niklason during our evening program hosted during AAST. They shared more information about their experience during our Vascular Trauma clinical trial’s V005 and V017 with our investigational Acellular Tissue Engineered Vessel (ATEV). Thank you everyone for making this an interactive, educational event. Stay connected on social for future educational events and learn more at?https://humacyte.com.? The Acellular Tissue Engineered Vessel is an investigational product and has not been approved for sale by the FDA or any regulatory agency. #AAST2024 #Biotech #Humacyte

Durham-based Humacyte has reported more positive long-term results from its #bioengineered blood vessels used to treat wartime #vascular injuries in Ukraine. Full story at: https://hubs.ly/Q02Pv0fz0

We are here and ready for you! Visit us at Booth # 212. Don’t wait till the end of the conference to see our investigational bioengineered human tissue.? Learn about our Acellular Tissue Engineered Vessel (ATEV) today. Find out more at https://humacyte.com/ #AAST2024 #Biotech #Humacyte The acellular tissue engineered vessel is investigational and has not been approved by the FDA or any regulatory agency.

We are looking forward to the American Association for the Surgery of Trauma Annual meeting starting next week! Come visit us at?Booth # 212?from?Wednesday, September 11th to Friday, September 13th. You can see and learn about our Acellular Tissue Engineered Vessel (ATEV). We can’t wait to connect. See you there! #AAST2024 #LearningTogether #Biotech #Humacyte

Thank you Dr. Shamik Parikh, for sharing during the breakout session at the Military Health System Research Symposium. He discussed the potential of ATEV as a possible durable, off-the-shelf solution for combat surgical teams in a real-world setting. Highlights of long-term results from patients with wartime injuries treated in our Ukraine Humanitarian Program: ???12-month patency rate:?87.1%? ???Zero infections, amputations, or deaths?during follow-up? ???Effective in severe wartime injuries?including mine blasts and high-velocity ballistics Read more in our latest press release here: https://lnkd.in/dZiDbSRF The acellular tissue engineered vessel is investigational and has not been approved by FDA or any regulatory agency. #Humacyte #MHSRS #Biotech #Clinicalstudy

What a conference! We have enjoyed getting to see so many at MHSRS.??If you haven’t visited us at Booth # 1120 don’t miss out an opportunity to ask our team questions or see our investigational ATEV for yourself. #Humacyte #MHSRS #Biotech The acellular tissue engineered vessel is investigational and has not been approved by the FDA or any regulatory agency.

Dr. Shamik Parikh, the Chief Medical Officer at Humacyte, will be presenting on Monday, August 26th?at the Military Health System Research Symposium in Florida.??During the Scientific Abstracts of Distinction Plenary session, Shamik’s presentation starts at 1330/1:30 and will be focused on the clinical trial of the Acellular Tissue Engineered Vessels (ATEV) in a military setting. We hope you come by and hear his presentation. ?We will also be at booth #1120 Monday through Wednesday.??Please come and speak with the medical affairs team to learn more about our investigational ATEV. The acellular tissue engineered vessel is investigational and has not been approved by FDA or any regulatory agency.

Humacyte?made significant strides in the second quarter of 2024 to further our mission to improve patient’s lives and transform the practice of medicine.?Laura Niklason MD and PhD, founder and CEO of Humacyte and Dale Sander, Chief Financial Officer, Chief Corporate Development Officer, Treasurer shared our Q2 2024 results on August 13th, 2024. FDA Extends Review of ATEV? BLA for Vascular Trauma: The FDA notified Humacyte that additional time is needed to complete the review of the Biologics License Application (BLA) for the acellular tissue engineered vessel (ATEV) in vascular trauma, a first-in-class product granted Priority Review. Humacyte remains confident in the approvability of ATEV. ATEV Shows Positive Patency Results in Phase 3 Hemodialysis Access Trial: Topline results from the V007 Phase 3 trial (N=242) demonstrated ATEV's positive functional patency at 6 and 12 months (co-primary endpoints; p=0.0071) and significantly longer hemodialysis duration over 12 months (p=0.0162) compared to autogenous fistula, the current standard of care. ATEV Receives 3rd RMAT Designation for Advanced PAD: The FDA granted ATEV its third Regenerative Medicine Advanced Therapy (RMAT) designation for treatment of advanced peripheral artery disease (PAD), recognizing its potential impact for patients facing amputation. Progress in CABG and BioVascular Pancreas Programs: Humacyte reported progress across its pipeline, including promising preclinical results for the BioVascular Pancreas in type 1 diabetes, and positive 6-month primate data on ATEV remodeling for coronary artery bypass grafts. We are proud of these milestones and look forward to sharing more at upcoming medical meetings. Thank you to our dedicated team and partners for making these advancements possible! View the full press release here: https://lnkd.in/eTYJcP6H The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. #Humacyte #BiotechInnovation #Biotech $HUMA

New speakers added! Save the date for the 9th Annual #MbDsymposium. Taking place December 9 at the MaRS Discovery District, Auditorium. We look forward?to hearing talks from the following #MbD investigators,?Gary Bader (University of Toronto), Kullervo Hynynen (Sunnybrook Research Institute), Elmar Jaeckel (University Health Network), Sonya MacParland (University Health Network), Cristina Nostro (University Health Network), Milica Radisic (University of Toronto), and Trevor Reichman (University of Toronto). Plenary talks by Anna Falk (CCRM Nordic, Lund University), Laura Niklason, MD, PhD (Humacyte, Yale University), Philip Tagari (insitro) and Fyodor Urnov (Innovative Genomics Institute, University of California, Berkeley) Registration opens September 5th. Learn more:?https://lnkd.in/gkCpSUPQ

Humacyte’s ATEV Evaluated for AV Access in Hemodialysis in Phase 3 Trial